Additionally, real-world pharmacovigilance data highlight sensory adverse events (particularly dysgeusia) that appear more frequently in clinical practice than in controlled trials, suggesting under recognition of taste-related disturbances in research settings (159)
Complementary findings in dietary obesity models have also been reported, where AgRP levels were elevated under hyperphagic conditions and reduced with food restriction, while -MSH and POMC concentrations remained unchanged [60]
Meaning, patients must try other medications (lower-cost alternatives) before Wegovy will be approved
Similarly, those with a history of motion sickness or medication-induced nausea may be more susceptible
While it is not FDA-approved for weight loss, some patients may lose weight as a secondary effect when using it with diet and exercise
Studied in preclinical models of tissue repair and gastrointestinal research